GPBAR1 and metabolic dysfunction-associated steatotic liver disease: However, the evidence on mechanisms of UDCA treatment for NAFLD via the TGR5 pathway is limited, which is possibly ascribed to the less abundance of TGR5 on hepatic parenchymal cells.